Back to Browse Journals » Cancer Management and Research » Volume 1

Bortezomib in the management of multiple myeloma

Authors Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Published Date September 2009 Volume 2009:1 Pages 107—117

DOI http://dx.doi.org/10.2147/CMAR.S4555

Published 8 September 2009

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G Richardson

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.

Keywords: multiple myeloma, bortezomib, stem cell transplantation, peripheral neuropathy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

Paul Richardson, Constantine Mitsiades, Jacob Laubach, et al

Core Evidence 2009, 4:215-245

Published Date: 17 November 2009

Readers of this article also read:

Clinical issues of mucus accumulation in COPD

Osadnik CR, McDonald CF, Holland AE

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:301-302

Published Date: 25 March 2014

Prevalence of dementia in Al-Quseir city, Red Sea Governorate, Egypt [Corrigendum]

El Tallawy HN, Farghly WM, Badry R, Rageh TA, Shehata GA, Hakeem M NA, El Hamed MA, Sayd MAM, Hamed Y, Kandil MR

Clinical Interventions in Aging 2014, 9:129-130

Published Date: 10 January 2014

Are calcifying microvesicles another analogous substructure of calcifying nanoparticles?

Atughonu TC, Arja SB, Shiekh FA

International Journal of Nanomedicine 2013, 8:4673-4676

Published Date: 5 December 2013

Response to vitamin D and depression in geriatric primary care patients

Muc-Wierzgoń M, Nowakowska-Zajdel E, Klakla K, Dzięgielewska-Gęsiak S, Fatyga E, Kokot T

Clinical Interventions in Aging 2013, 8:825-827

Published Date: 3 July 2013

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia

Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH

Clinical Interventions in Aging 2013, 8:431-432

Published Date: 16 April 2013

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011